RTKs: Precision Cancer Therapy Targets
Credit: Sino Biological
Receptor tyrosine kinases (RTKs) are pivotal in both normal cellular functions and cancer progression, activating critical signaling pathways. In cancer therapy, targeted therapies using monoclonal antibodies and small molecule drugs against RTKs such as ALK, AXL, c-Kit, and c-Met, have shown substantial success in treating various cancers. Sino Biological's recombinant proteins being utilized in research on RTK binding specificities and therapeutic approaches. The merger between Sino Biological and SignalChem Biotech (SCB) further enhances research capabilities by offering a comprehensive range of RTK domains for both monoclonal antibody and small molecule drug development, advancing the field of precision cancer therapies.
